Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)
2019
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
22
Citations
NaN
KQI